neuroinflammation

Phase 1Small molecule

NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

neuroinflammation is one of 5 small molecule programs targeting Alcohol Use Disorder (AUD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol Use Disorder (AUD)Completed

Alcohol Use Disorder (AUD)Phase 1

Completed

Competition

Competitive Landscape

5 competitors in Alcohol Use Disorder (AUD)

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 2

1 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

2 3

Zonegran

AAzurity Pharmaceuticals

Phase 2

1 4

Epidiolex

Jazz Pharmaceuticals

Preclinical

1 5

neuroinflammation

NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Use Disorder (AUD)1 trial

Brain Inflammation and Function in Alcoholism

Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 1·NCT02233868·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for neuroinflammation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neuroinflammation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neuroinflammation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute on Alcohol Abuse and Alcoholism (NIAAA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

neuroinflammation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Use Disorder (AUD)1 trial

References

Drug Info

Quick Facts

Related News